CA
NZ
UK
AU
IND
US
Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) delivered news on two consecutive days this month. On 6 August 2026 the micro-cap regenerative medicine developer said the U.S. Patent andTrademarkOffice had allowed another patent covering its cell-free approach to type 1 diabetes. A day later it …
GT Biopharma, Inc. (NASDAQ:GTBP) is a clinical-stage cancer company built on one platform. TriKE, short for tri-specific killer engager, is a laboratory-built protein designed to grab a patient's natural killer (NK) cells, hold them against a tumour cell and switch them on.
IN8bio, Inc. (NASDAQ:INAB) is a small New York biotech built around gamma-delta T cells - an uncommon immune cell that attacks tumours without the tissue-matching signals conventional T cells need. It engineers them to survive chemotherapy, a platform called DeltEx DRI, and is testing …
Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) is a Los Angeles clinical-stage oncology company built on one idea: tumours that stop responding to good drugs can be made to respond again. Its lead candidate, ENV-105 (carotuximab), is an antibody targeting CD105, a protein cancer cells display to …
Vyome Holdings, Inc. (NASDAQ:HIND) spent the first half of 2026 adding cash while holding research spending in the low seven figures. ItsQuarterly Reportfiled on 12 August showed $7.9 million of cash, no debt, and a lead candidate that has already produced statistically significant Phase …
AEON Biopharma, Inc. (NYSEAMERICAN:AEON) has spent 18 months trading with an asterisk on its ticker. On 3 August 2026 the Irvine, California drug developer said it had regained compliance with the exchange's continued listing standards, ending a deficiency dating to February 2025.
Autonomix Medical, Inc. (NASDAQ:AMIX) has spent the summer of 2026 doing two things at once: pushing a novel medical device toward the U.S. Food and Drug Administration, and working to keep enough cash in the bank to get there.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) has spent 2026 rebuilding itself in public. In eight months it has replaced its chief executive, hired an entirely new senior team, abandoned the single-asset strategy it was built on, and raised more money than it had ever held at …
enVVeno Medical Corporation (NASDAQ:NVNO) is a small Irvine, California device developer attacking severe deep chronic venous insufficiency, or CVI. In a healthy leg, one-way valves inside the deep veins stop blood falling back toward the feet. When those valves are destroyed, blood pools, and …
GRI Bio, Inc. (NASDAQ:GRI) is among the smallest clinical-stage biotechs on theNasdaqCapitalMarket, yet it carries one of the more intriguing mid-stage datasets in idiopathic pulmonary fibrosis. The La Jolla, California company closed at $1.95 on 12 August 2026 - aMarket Valuenear $3.5 million across …
Please wait processing your request...